{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:12:05Z","timestamp":1790957525276,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003810","name":"Hospital de Cl\u00ednicas de Porto Alegre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003810","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00125-025-06633-x","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T02:58:58Z","timestamp":1766545138000},"page":"1150-1163","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of insulin regimens for type 2 diabetes mellitus: a systematic review and network meta-analysis"],"prefix":"10.1007","volume":"69","author":[{"suffix":"Jr","given":"Vanderlei C.","family":"Bertuol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Iorra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarsila","family":"Vieceli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole T.","family":"Tonolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Zappelini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiza","family":"van der Sand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiane B.","family":"Leit\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitris V.","family":"Rados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"issue":"8","key":"6633_CR1","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.3390\/molecules25081987","volume":"25","author":"A Artasensi","year":"2020","unstructured":"Artasensi A, Pedretti A, Vistoli G, Fumagalli L (2020) Type 2 diabetes mellitus: a review of multi-target drugs. Molecules 25(8):1987. https:\/\/doi.org\/10.3390\/molecules25081987","journal-title":"Molecules"},{"issue":"Suppl 1","key":"6633_CR2","doi-asserted-by":"publisher","first-page":"S140","DOI":"10.2337\/dc23-S009","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR et al (2023) 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023. Diabetes Care 46(Suppl 1):S140\u2013S157. https:\/\/doi.org\/10.2337\/dc23-S009","journal-title":"Diabetes Care"},{"issue":"23","key":"6633_CR3","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMsa2032271","volume":"384","author":"M Fang","year":"2021","unstructured":"Fang M, Wang D, Coresh J, Selvin E (2021) Trends in diabetes treatment and control in U.S. adults, 1999-2018. N Engl J Med 384(23):2219\u20132228. https:\/\/doi.org\/10.1056\/NEJMsa2032271","journal-title":"N Engl J Med"},{"issue":"3","key":"6633_CR4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/j.1463-1326.2011.01512.x","volume":"14","author":"K Esposito","year":"2012","unstructured":"Esposito K, Chiodini P, Bellastella G, Maiorino MI, Giugliano D (2012) Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. Diabetes Obes Metab 14(3):228\u2013233. https:\/\/doi.org\/10.1111\/j.1463-1326.2011.01512.x","journal-title":"Diabetes Obes Metab"},{"issue":"23","key":"6633_CR5","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1001\/jama.2020.1303","volume":"323","author":"IB Hirsch","year":"2020","unstructured":"Hirsch IB, Gaudiani LM (2020) Using insulin to treat poorly controlled type 2 diabetes in 2020. JAMA 323(23):2419\u20132420. https:\/\/doi.org\/10.1001\/jama.2020.1303","journal-title":"JAMA"},{"issue":"Supplement_1","key":"6633_CR6","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.2337\/dc25-S009","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee (2025) 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025. Diabetes Care 48(Supplement_1):S181\u2013S206. https:\/\/doi.org\/10.2337\/dc25-S009","journal-title":"Diabetes Care"},{"issue":"6","key":"6633_CR7","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/dom.13653","volume":"21","author":"GE Umpierrez","year":"2019","unstructured":"Umpierrez GE, Skolnik N, Dex T, Traylor L, Chao J, Shaefer C (2019) When basal insulin is not enough: A dose-response relationship between insulin glargine 100 units\/mL and glycaemic control. Diabetes Obes Metab 21(6):1305\u20131310. https:\/\/doi.org\/10.1111\/dom.13653","journal-title":"Diabetes Obes Metab"},{"issue":"18","key":"6633_CR8","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1056\/NEJMoa0905479","volume":"361","author":"RR Holman","year":"2009","unstructured":"Holman RR, Farmer AJ, Davies MJ et al (2009) Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 361(18):1736\u20131747. https:\/\/doi.org\/10.1056\/NEJMoa0905479","journal-title":"N Engl J Med"},{"issue":"10","key":"6633_CR9","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1111\/dom.12955","volume":"19","author":"HW Rodbard","year":"2017","unstructured":"Rodbard HW, Tripathy D, Vidrio Vel\u00e1zquez M, Demissie M, Tamer SC, Pileti\u010d M (2017) Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18-week, open-label, phase 3 trial (onset 3). Diabetes Obes Metab 19(10):1389\u20131396. https:\/\/doi.org\/10.1111\/dom.12955","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"6633_CR10","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1007\/s00125-009-1468-7","volume":"52","author":"DS Lasserson","year":"2009","unstructured":"Lasserson DS, Glasziou P, Perera R, Holman RR, Farmer AJ (2009) Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia 52(10):1990\u20132000. https:\/\/doi.org\/10.1007\/s00125-009-1468-7","journal-title":"Diabetologia"},{"issue":"6","key":"6633_CR11","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/S2213-8587(23)00093-1","volume":"11","author":"A Philis-Tsimikas","year":"2023","unstructured":"Philis-Tsimikas A, Asong M, Franek E et al (2023) Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial. Lancet Diabetes Endocrinol 11(6):414\u2013425. https:\/\/doi.org\/10.1016\/S2213-8587(23)00093-1","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"6633_CR12","doi-asserted-by":"publisher","first-page":"CD005613","DOI":"10.1002\/14651858.CD005613.pub4","volume":"11","author":"T Semlitsch","year":"2020","unstructured":"Semlitsch T (2020) Ultra-long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev 11(11):CD005613. https:\/\/doi.org\/10.1002\/14651858.CD005613.pub4","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"6633_CR13","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/s12020-021-02889-6","volume":"74","author":"E Mannucci","year":"2021","unstructured":"Mannucci E, Caiulo C, Naletto L, Madama G, Monami M (2021) Efficacy and safety of different basal and prandial insulin analogues for the treatment of type 2 diabetes: a network meta-analysis of randomized controlled trials. Endocrine 74(3):508\u2013517. https:\/\/doi.org\/10.1007\/s12020-021-02889-6","journal-title":"Endocrine"},{"issue":"12","key":"6633_CR14","doi-asserted-by":"publisher","first-page":"CD013228","DOI":"10.1002\/14651858.CD013228","volume":"12","author":"B Fullerton","year":"2018","unstructured":"Fullerton B, Siebenhofer A, Jeitler K et al (2018) Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus. Cochrane Database Syst Rev 12(12):CD013228. https:\/\/doi.org\/10.1002\/14651858.CD013228","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"6633_CR15","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777\u2013784. https:\/\/doi.org\/10.7326\/M14-2385","journal-title":"Ann Intern Med"},{"key":"6633_CR16","unstructured":"Shanaa A (2021) Rayyan - AI powered tool for systematic literature reviews. Available from https:\/\/www.rayyan.ai\/. Accessed 16 Oct 2023"},{"key":"6633_CR17","unstructured":"Higgins JPT, Li T, Deeks JJ (2023) Chapter 6: Choosing effect measures and computing estimates of effect. Available from https:\/\/training.cochrane.org\/handbook\/current\/chapter-06#section-6-5-2-7. Accessed 11 Feb 2025"},{"key":"6633_CR18","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"issue":"4","key":"6633_CR19","doi-asserted-by":"publisher","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","volume":"17","author":"A Nikolakopoulou","year":"2020","unstructured":"Nikolakopoulou A, Higgins JPT, Papakonstantinou T et al (2020) CINeMA: An approach for assessing confidence in the results of a network meta-analysis. PLoS Med 17(4):e1003082. https:\/\/doi.org\/10.1371\/journal.pmed.1003082","journal-title":"PLoS Med"},{"issue":"2","key":"6633_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v106.i02","volume":"106","author":"S Balduzzi","year":"2023","unstructured":"Balduzzi S, R\u00fccker G, Nikolakopoulou A et al (2023) netmeta: An R package for network meta-analysis using frequentist methods. J Stat Softw 106(2):1\u201340. https:\/\/doi.org\/10.18637\/jss.v106.i02","journal-title":"J Stat Softw"},{"key":"6633_CR21","doi-asserted-by":"publisher","DOI":"10.1201\/9781003107347","volume-title":"Doing meta-analysis with R: a hands-on guide","author":"M Harrer","year":"2021","unstructured":"Harrer M, Cuijpers P, Furukawa TA, Ebert DD (2021) Doing meta-analysis with R: a hands-on guide. Chapman & Hall\/CRC Press, New York"},{"issue":"7","key":"6633_CR22","doi-asserted-by":"publisher","first-page":"e99682","DOI":"10.1371\/journal.pone.0099682","volume":"9","author":"G Salanti","year":"2014","unstructured":"Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JPT (2014) Evaluating the quality of evidence from a network meta-analysis. PLoS One 9(7):e99682. https:\/\/doi.org\/10.1371\/journal.pone.0099682","journal-title":"PLoS One"},{"key":"6633_CR23","unstructured":"Chaimani A, Caldwell DM, Li T, Higgins JPT, Salanti G (2022) Chapter 11: Undertaking network meta-analyses. https:\/\/training.cochrane.org\/handbook\/current\/chapter-11. Accessed 25 Mar 2024"},{"issue":"11","key":"6633_CR24","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1111\/j.1463-1326.2011.01459.x","volume":"13","author":"DR Owens","year":"2011","unstructured":"Owens DR, Luzio SD, Sert-Langeron C, Riddle MC (2011) Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month \u201cproof-of-concept\u201d study. Diabetes Obes Metab 13(11):1020\u20131027. https:\/\/doi.org\/10.1111\/j.1463-1326.2011.01459.x","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"6633_CR25","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1111\/dme.13518","volume":"34","author":"U Anyanwagu","year":"2017","unstructured":"Anyanwagu U, Mamza J, Gordon J, Donnelly R, Idris I (2017) Premixed vs basal-bolus insulin regimen in Type 2 diabetes: comparison of clinical outcomes from randomized controlled trials and real-world data. Diabet Med 34(12):1728\u20131736. https:\/\/doi.org\/10.1111\/dme.13518","journal-title":"Diabet Med"},{"issue":"3","key":"6633_CR26","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s12020-015-0718-3","volume":"51","author":"D Giugliano","year":"2016","unstructured":"Giugliano D, Chiodini P, Maiorino MI, Bellastella G, Esposito K (2016) Intensification of insulin therapy with basal-bolus or premixed insulin regimens in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Endocrine 51(3):417\u2013428. https:\/\/doi.org\/10.1007\/s12020-015-0718-3","journal-title":"Endocrine"},{"issue":"5","key":"6633_CR27","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/dme.12694","volume":"32","author":"C Wang","year":"2015","unstructured":"Wang C, Mamza J, Idris I (2015) Biphasic vs basal bolus insulin regimen in Type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabet Med 32(5):585\u2013594. https:\/\/doi.org\/10.1111\/dme.12694","journal-title":"Diabet Med"},{"issue":"1","key":"6633_CR28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.amjms.2023.04.003","volume":"366","author":"R Bai","year":"2023","unstructured":"Bai R, Batra K, Yap C, Izuora K (2023) Diabetes-related outcomes with basal-bolus vs premixed insulin among veterans with type 2 diabetes: a single institutional retrospective study. Am J Med Sci 366(1):38\u201343. https:\/\/doi.org\/10.1016\/j.amjms.2023.04.003","journal-title":"Am J Med Sci"},{"issue":"5","key":"6633_CR29","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s13300-021-01041-x","volume":"12","author":"H Miyoshi","year":"2021","unstructured":"Miyoshi H, Baxter M, Kimura T et al (2021) A real-world, observational study of the initiation, use, and effectiveness of basal-bolus or premixed insulin in Japanese people with type 2 diabetes. Diabetes Ther 12(5):1341\u20131357. https:\/\/doi.org\/10.1007\/s13300-021-01041-x","journal-title":"Diabetes Ther"},{"issue":"2","key":"6633_CR30","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.diabres.2015.01.030","volume":"108","author":"PD Home","year":"2015","unstructured":"Home PD, Dain M-P, Freemantle N et al (2015) Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents. Diabetes Res Clin Pract 108(2):350\u2013359. https:\/\/doi.org\/10.1016\/j.diabres.2015.01.030","journal-title":"Diabetes Res Clin Pract"},{"key":"6633_CR31","doi-asserted-by":"crossref","unstructured":"(1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352(9131):837\u2013853","DOI":"10.1016\/S0140-6736(98)07019-6"},{"issue":"24","key":"6633_CR32","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","volume":"358","author":"A Patel","year":"2008","unstructured":"ADVANCE Collaborative Group, Patel A, MacMahon S et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358(24):2560\u20132572. https:\/\/doi.org\/10.1056\/NEJMoa0802987","journal-title":"N Engl J Med"},{"issue":"24","key":"6633_CR33","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"HC Gerstein","year":"2008","unstructured":"Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358(24):2545\u20132559. https:\/\/doi.org\/10.1056\/NEJMoa0802743","journal-title":"N Engl J Med"},{"issue":"11","key":"6633_CR34","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1007\/s00125-009-1470-0","volume":"52","author":"FM Turnbull","year":"2009","unstructured":"Control Group, Turnbull FM, Abraira C et al (2009) Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52(11):2288\u20132298. https:\/\/doi.org\/10.1007\/s00125-009-1470-0","journal-title":"Diabetologia"},{"issue":"7","key":"6633_CR35","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S2213-8587(25)00096-8","volume":"13","author":"C Mathieu","year":"2025","unstructured":"Mathieu C, Giorgino F, Kim SG et al (2025) Once-weekly IcoSema versus once-weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open-label, multicentre, treat-to-target, randomised, phase 3a trial. Lancet Diabetes Endocrinol 13(7):568\u2013579. https:\/\/doi.org\/10.1016\/S2213-8587(25)00096-8","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"6633_CR36","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1111\/dom.13343","volume":"20","author":"MI Maiorino","year":"2018","unstructured":"Maiorino MI, Chiodini P, Bellastella G et al (2018) Free and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab 20(9):2309\u20132313. https:\/\/doi.org\/10.1111\/dom.13343","journal-title":"Diabetes Obes Metab"},{"issue":"23","key":"6633_CR37","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1056\/NEJMoa2403953","volume":"391","author":"C Wysham","year":"2024","unstructured":"Wysham C, Bajaj HS, Del Prato S et al (2024) Insulin efsitora versus degludec in type 2 diabetes without previous insulin treatment. N Engl J Med 391(23):2201\u20132211. https:\/\/doi.org\/10.1056\/NEJMoa2403953","journal-title":"N Engl J Med"},{"issue":"7","key":"6633_CR38","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S2213-8587(25)00052-X","volume":"13","author":"LK Billings","year":"2025","unstructured":"Billings LK, Andreozzi F, Frederiksen M et al (2025) Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial. Lancet Diabetes Endocrinol 13(7):556\u2013567. https:\/\/doi.org\/10.1016\/S2213-8587(25)00052-X","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"6633_CR39","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00125-024-06348-5","volume":"68","author":"I Lingvay","year":"2025","unstructured":"Lingvay I, Benamar M, Chen L et al (2025) Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial. Diabetologia 68(4):739\u2013751. https:\/\/doi.org\/10.1007\/s00125-024-06348-5","journal-title":"Diabetologia"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-025-06633-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-025-06633-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-025-06633-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T16:46:11Z","timestamp":1774111571000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-025-06633-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["6633"],"URL":"https:\/\/doi.org\/10.1007\/s00125-025-06633-x","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"24 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study uses secondary data from the primary studies listed in the\n                      \n                      .","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"This research was supported by grants and material support from the Committee for the Development of Higher Education Personnel (CAPES) and the Hospital de Cl\u00ednicas de Porto Alegre \u2013 FIPE HCPA. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"CBL reports payment related to one lecture about obesity treatment. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 relationships and activities"}},{"value":"VCBJ contributed to data collection and analysis, drafted the first version of the manuscript, and approved the final version. FI was involved in study conceptualisation, participated in data collection and approved the final manuscript. TV, NTT, RZ and LVS each contributed to data collection and approved the final version of the manuscript. CBL contributed to study conceptualisation, revised the manuscript and approved the final version. DVR led the study conceptualisation, design and oversight, contributed to data analysis, participated in manuscript writing and approved the final version. All listed authors contributed to preparing and approving the manuscript and followed the International Committee of Medical Journal Editors (ICMJE) criteria for authorship. VCBJ and DVR had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}}]}}